文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

马拉维结合疫苗前侵袭性肺炎球菌的群体遗传结构、抗生素耐药、荚膜转换与进化

Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi.
PubMed 文献 · Vaccine · 2017-07-12

本研究对马拉维2004至2010年PCV13实施前的585株侵袭性肺炎球菌分离株进行回顾性全基因组测序,分析群体遗传结构、血清型流行率、抗生素耐药率及荚膜转换。结果显示22个遗传序列簇,血清型1(ST217)流行率最高(19.3%)且多重耐药率最高(81.9%),非疫苗血清型12F多重耐药率为57.9%。荚膜转换在无疫苗选择压力下自然发生,高流行荚膜转换株多与获得疫苗靶向荚膜相关。

要点

  • 血清型1(ST217)流行率19.3%,多重耐药率81.9%,均为最高。
  • 非疫苗血清型12F多重耐药率57.9%,有疫苗后血清型替换潜力。
  • 疫苗前已存在自然荚膜转换,高流行转换株多获得疫苗靶向荚膜。

核心结论

  • 本研究描述了荚膜转换血清型及接种后可能引起血清型替换的血清型(如12F),持续监测对设计更好的感染防控措施(如将新出现的替换血清型纳入未来结合疫苗)至关重要。

研究设计与样本

  • 回顾性对2004至2010年585株侵袭性肺炎球菌分离株进行全基因组测序,样本来自马拉维PCV13实施前。

主要发现

  • 群体结构分析显示22个遗传上不同的序列簇(SCs),由密切相关的分离株组成。
  • 血清型1(ST217)属于分支SC2,流行率最高(19.3%),多重耐药率最高(81.9%)。
  • 血清型12F属于分支SC10的非疫苗血清型,多重耐药率为57.9%。
  • 2010年分支SC1中PMEN19克隆(血清型5 ST289)增加,提示可能的未检测到的局部暴发。
  • 合并分析显示SCs近期出现,并有证据表明在无疫苗诱导选择压力下发生自然荚膜转换,多数高流行荚膜转换分离株与获得疫苗靶向荚膜相关。

关键数值与推荐

  • 血清型1(ST217)流行率19.3%,多重耐药率81.9%。
  • 血清型12F多重耐药率57.9%。

临床怎么用

  • 作者认为持续监测至关重要,以监测这些血清型和抗生素耐药,从而设计更好的感染防控措施,如将新出现的替换血清型纳入未来结合疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pneumococcal infections cause a high death toll in Sub Saharan Africa (SSA) but the recently rolled out pneumococcal conjugate vaccines (PCV) will reduce the disease burden. To better understand the population impact of these vaccines, comprehensive analysis of large collections of pneumococcal isolates sampled prior to vaccination is required. Here we present a population genomic study of the invasive pneumococcal isolates sampled before the implementation of PCV13 in Malawi. MATERIALS AND METHODS: We retrospectively sampled and whole genome sequenced 585 invasive isolates from 2004 to 2010. We determine the pneumococcal population genetic structure and assessed serotype prevalence, antibiotic resistance rates, and the occurrence of serotype switching. RESULTS: Population structure analysis revealed 22 genetically distinct sequence clusters (SCs), which consisted of closely related isolates. Serotype 1 (ST217), a vaccine-associated serotype in clade SC2, showed highest prevalence (19.3%), and was associated with the highest MDR rate (81.9%) followed by serotype 12F, a non-vaccine serotype in clade SC10 with an MDR rate of 57.9%. Prevalence of serotypes was stable prior to vaccination although there was an increase in the PMEN19 clone, serotype 5 ST289, in clade SC1 in 2010 suggesting a potential undetected local outbreak. Coalescent analysis revealed recent emergence of the SCs and there was evidence of natural capsule switching in the absence of vaccine induced selection pressure. Furthermore, majority of the highly prevalent capsule-switched isolates were associated with acquisition of vaccine-targeted capsules. CONCLUSIONS: This study provides descriptions of capsule-switched serotypes and serotypes with potential to cause serotype replacement post-vaccination such as 12F. Continued surveillance is critical to monitor these serotypes and antibiotic resistance in order to design better infection prevention and control measures such as inclusion of emerging replacement serotypes in future conjugate vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chaguza C, Cornick JE, Andam CP, et al. Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi. Vaccine. 2017. PMID: 28711389. doi:10.1016/j.vaccine.2017.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。